# Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

> **NCT05060237** · PHASE1 · COMPLETED · sponsor: **Biofrontera Bioscience GmbH** · enrollment: 112 (actual)

## Conditions studied

- Actinic Keratosis
- Keratosis, Actinic
- Keratosis

## Interventions

- **COMBINATION_PRODUCT:** BF-200 ALA and red light LED lamp

## Key facts

- **NCT ID:** NCT05060237
- **Lead sponsor:** Biofrontera Bioscience GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-01
- **Primary completion:** 2023-04-20
- **Final completion:** 2023-04-20
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05060237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05060237, "Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05060237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*